查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403395

透纳氏症市场预测至 2030 年：按类型、药物类型、治疗类型、诊断、给药途径、最终用户和地区进行的全球分析

Turner Syndrome Market Forecasts to 2030 - Global Analysis By Type, Drug Type, Therapy Type, Diagnosis, Route Of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球透纳氏症市场规模为 42.3 亿美元，预计到 2030 年将达到 72.9 亿美元，预测期内复合年增长率为 8.1%。

透纳氏症是一种影响女性的染色体疾病，由 X 染色体缺失或不完整所引起。女性通常有两条 X 染色体 (XX)，但透纳氏症患者要么缺少一条 X 染色体 (X0)，要么其中一条 X 染色体出现异常。患有透纳氏症的女孩通常具有特异性的身体特征，例如身材矮小、网状颈部（额外的皮肤褶皱）、宽阔的胸部、低位耳朵和高位上颚。

根据国家医学图书馆 2017 年的数据，全球每 2,500 名新生儿中约有 1 名患有透纳氏症。

提高患者的宣传和意识

患者倡导在倡导改善医疗保健服务和治疗的可近性方面发挥重要作用。它通常延伸到旨在改善透纳氏症罕见疾病患者整体环境的政策倡议。提高认识通常可以早期发现透纳氏症。他们在提高认识、支持研究和倡导更好的治疗选择方面发挥着重要作用。这些团体促进研究人员、临床医生和製药公司之间的合作。

病患人数有限

透纳氏症是一种罕见疾病，每 2,000 名女孩中就有 1 人受到影响。因此，几乎没有机会获得对于了解疾病进展很重要的自然史资料。由于患者数量有限，很难收集足够的真实世界证据，这可能会妨碍了解治疗方法的长期效果。此外，确定治疗方法价值并确保报销可能更加复杂。这些方面增加了复杂性并阻碍了市场成长。

未满足的医疗需求

透纳氏症是一种罕见疾病，有一些未满足的医疗需求需要有效的标靶治疗。解决这些未满足的医疗需求需要医疗保健专业人员、研究人员和製药公司之间的合作。标靶治疗治疗的发展可以显着改善透纳氏症的治疗，并带来更有效和个体化的治疗选择。製药公司可能会将此视为开发创新治疗方法和加速市场扩张的机会。

开发成本高

开发针对透纳氏症罕见疾病的治疗方法通常面临独特的挑战，从而导致急剧上升的开发成本。由于潜在患者数量有限，製药公司在经济上很难投资开发透纳氏症的药物和治疗方法。此外，了解潜在的遗传机制、进行临床前研究以及引导罕见疾病的监管流程需要专门的知识和资源。这些因素的结合可能会阻碍市场的成长。

COVID-19 的影响

全球医疗保健服务受到 COVID-19 疫情的严重影响。这场大流行已经转移了资源并推迟了透纳氏症非紧急医疗状况的治疗。患者在获得常规检查、治疗和支持服务方面面临挑战。此外，製药业的供应链经历了中断，影响了与透纳氏症相关的药品和其他医疗用品的供应。市场也已恢復至疫情前的水准。

预计 Genotropin 细分市场在预测期内将是最大的

估计 Genotropin 细分市场将出现良好的成长。 Genotropin 通常用作综合治疗方法的一部分，包括荷尔蒙替代疗法和其他干预措施，以解决透纳氏症的各个方面。 Genotropin 有助于改善透纳氏症患者的生活品质。它具有许多好处，包括改善身体组成、骨骼健康、心血管健康、改善身材矮小和整体身体生长。

产前检测领域预计在预测期内复合年增长率最高

预计产前检测领域在预测期内将呈现最高的复合年增长率。产前检测在透纳氏症的早期诊断中发挥重要作用。这种早期诊断可能会导致及时介入和适当的管理策略，从而改善受影响个体的结果。了解怀孕期间的疾病可以帮助父母做好心理准备，并应对与疾病相关的挑战。随着技术和基因检测的不断进步，透纳氏症的产前检测将变得更加准确和方便，进一步增强其在患者照护和计划生育中的作用。

比最大的地区

由于人们对女性健康意识的提高、医疗保健支出的增加以及医疗保健行业的增长，预计亚太地区将在预测期内占据最大的市场占有率。印度的医疗保健产业是成长最快的产业之一。印度和中国等新兴国家正大力投资医疗基础设施、医疗专家和研发活动。因此，支出的增加加上女性遗传疾病数量的定期增加，导致该地区透纳氏症市场的成长。

复合年增长率最高的地区：

预计欧洲在预测期内的复合年增长率最高。欧洲是诺华 (Novartis)、益普生 (Ipsen) 和赛诺菲健赞 (Sanofi-Genzyme) 等主要企业的所在地。这些公司正在大力投资罕见遗传疾病的研究。这些公司通常提供最新的创新和解决方案。此外，罕见疾病领域不断涌现的技术创新、庞大的患者群体、对唐氏症的认识不断增强以及生物技术领域的成长正在推动该地区的市场成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球透纳氏症市场：依类型

  • 马赛克特纳透纳氏症
  • 经典透纳氏症

第六章全球透纳氏症市场：依药物类型

  • 氧雄龙
  • 氧山德碱
  • 去甲肾上腺素
  • 生长激素
  • 促基因素
  • 人马托
  • 佐马酮
  • 嗜中性球素

第七章全球透纳氏症市场：依治疗类型

  • 黄体酮替代疗法
  • 雌激素替代疗法
  • 生长激素治疗
  • 心理治疗
  • 其他治疗方法

第八章全球透纳氏症市场：依诊断

  • 体检
  • 核型分析
  • 产前检测
    • 羊膜穿刺术
    • 超音波检查
    • 绒毛膜绒毛取样
  • 其他诊断

第九章全球透纳氏症市场：依给药途径

  • 口服
  • 皮下的
  • 静脉
  • 肌肉注射
  • 其他给药途径

第 10 章全球透纳氏症市场：依最终用户分类

  • 调查机构
  • 医院和诊所
  • 学术机构
  • 其他最终用户

第十一章全球透纳氏症市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Smiths Group
  • Pfizer Inc.
  • Rocket Medical PLC
  • Medtronic
  • Novo Nordisk
  • Sanofi
  • Cooper Pharma
  • Eli Lilly and Company
  • Genentech
  • Lupin Pharmaceuticals Inc
  • Sandoz International GmbH
  • AbbVie Inc.
  • Codexis
  • Merck & Co.
  • American Gene Technologies
  • Johnson & Johnson Services Inc
  • F. Hoffmann-La Roche Limited
  • Ultragenyx Pharmaceutical
  • Abbott Laboratories
  • BioMarin
Product Code: SMRC24620

According to Stratistics MRC, the Global Turner Syndrome Market is accounted for $4.23 billion in 2023 and is expected to reach $7.29 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Turner syndrome is a chromosomal condition that affects females and results from a missing or incomplete X chromosome. Typically, females have two X chromosomes (XX), but individuals with Turner syndrome have either a missing X chromosome (X0) or abnormalities in one of the X chromosomes. Girls with turner syndrome often have specific physical characteristics including short stature, a webbed neck (extra folds of skin), a broad chest, low-set ears, and a high-arched palate.

According to the National Library of Medicine in 2017, about 1 in 2,500 new-born girls, worldwide, were affected with the Turner Syndrome.

Market Dynamics:

Driver:

Rising patient advocacy and awareness

Patient advocacy plays a crucial role in advocating for improved access to healthcare services and treatments. It often extends to policy initiatives aimed at improving the overall landscape for individuals with rare diseases like turner syndrome. Increased awareness often leads to early detection of Turner syndrome. It plays a crucial role in raising awareness, supporting research, and advocating for better treatment options. These groups facilitates collaboration between researchers, clinicians, and pharmaceutical companies.

Restraint:

Limited patient population

Turner Syndrome is a rare disorder which occurs in mostly one out of 2000 girls. So, there is less availability of natural history data, which is crucial for understanding the progression of the disease. Limited patient numbers makes it challenging to gather sufficient real-world evidence, potentially hindering the understanding of the long-term impact of therapies. Also, establishing the value of a therapy and securing reimbursement can be more complex. This aspect raises the complexities and hampers the market growth.

Opportunity:

Unmet medical needs

Turner Syndrome is a rare disorder and it presents several unmet medical needs that need effective and targeted therapies. Addressing these unmet medical needs requires collaboration between healthcare professionals, researchers, and pharmaceutical companies. The development of targeted therapies could significantly improve the management of Turner Syndrome, potentially leading to more effective and personalized treatment options. Pharmaceutical companies may see this as an opportunity to develop innovative treatments which in turn accelerates the market expansion.

Threat:

High development costs

The development of therapies for rare conditions such as turner syndrome often faces unique challenges, leading to high development costs. The limited number of potential patients makes it economically challenging for pharmaceutical companies to invest in the development of drugs or therapies for turner syndrome. Also, understanding the underlying genetic mechanisms, conducting preclinical studies, and navigating the regulatory processes for rare diseases require specialized expertise and resources. The combination of these factors can hamper the growth of the market.

COVID-19 Impact

Global healthcare services have been severely impacted by the COVID-19 epidemic. Due to the pandemic, resources were redirected, which caused delays in the treatment of non-urgent medical disorders, such as Turner syndrome. Patients have faced challenges in accessing regular check-ups, treatments, and support services. Additionally, the supply chain for the pharmaceutical sector experienced interruptions that impacted the availability of drugs and other healthcare supplies related to Turner syndrome. The market has further recovered to its pre-pandemic level.

The genotropin segment is expected to be the largest during the forecast period

The genotropin segment is estimated to have a lucrative growth. Genotropin is often used as part of a comprehensive treatment approach that includes hormone replacement therapy and other interventions to address various aspects of turner syndrome. It contributes to an improved quality of life for individuals with turner syndrome. It exhibits numerous benefits such as improved body composition, bone health, cardiovascular health, improvement of short stature and overall body growth.

The prenatal testing segment is expected to have the highest CAGR during the forecast period

The prenatal testing segment is anticipated to witness the highest CAGR growth during the forecast period. Prenatal testing plays a crucial role in the early diagnosis of turner syndrome. This early diagnosis can lead to timely interventions and appropriate management strategies, potentially improving outcomes for the affected individual. Knowing about the disorder during pregnancy allows parents to emotionally prepare for the challenges associated with the condition. As technology and genetic testing methods continue to advance, the accuracy and accessibility of prenatal testing for turner syndrome are likely to improve, further enhancing its role in patient care and family planning.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing awareness for women health, rising healthcare expenditures and growing healthcare sector. The Indian healthcare sector was one of the fastest growing industries. The developing countries like the India and China are investing heavily on healthcare infrastructure, professional doctors and R&D activities. Therefore, the increasing expenditure coupled with rising regularity of genetic disorders in females leads to the growth of the turner syndrome market in this region.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is home to several key players such as Novartis, Ipsen and Sanofi Genzym. These companies invest hugely on research activities related to rare genetic diseases. They often bring out latest innovations and solutions. Further, rise in technological innovations for rare disorders, huge patient population, increasing awareness regarding down syndromes and growing biotechnology sector are boosting the region's market growth.

Key players in the market:

Some of the key players profiled in the Turner Syndrome Market include Smiths Group, Pfizer Inc., Rocket Medical PLC, Medtronic, Novo Nordisk, Sanofi, Cooper Pharma, Eli Lilly and Company, Genentech, Lupin Pharmaceuticals Inc, Sandoz International GmbH, AbbVie Inc., Codexis, Merck & Co., American Gene Technologies, Johnson & Johnson Services Inc, F. Hoffmann-La Roche Limited, Ultragenyx Pharmaceutical, Abbott Laboratories and BioMarin.

Key Developments:

In October 2023, Novo Nordisk, a subsidiary of Novo Holdings AS, unveils Somapacitan (Sogroya) is a human growth hormone analog. It is formulated as solution for subcutaneous route of administration. Sogroya is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (GHD).

In March 2023, Sanofi and Provention Bio Inc, have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc. The acquisition is a strategic fit for Sanofi at the intersection of the company's growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes.

Types Covered:

  • Mosaic Turner Syndrome
  • Classical Turner Syndrome

Drug Types Covered:

  • Oxandrolone
  • Oxandrin
  • Norditropin
  • Somatropin
  • Genotropin
  • Humatrope
  • Zomacton
  • Nutropin

Therapy Types Covered:

  • Progesterone Replacement Therapy
  • Oestrogen Replacement Therapy
  • Growth Hormone Therapy
  • Psychological Therapy
  • Other Therapy Types

Diagnosis Covered:

  • Physical Examination
  • Karyotyping
  • Prenatal Testing
  • Other Diagnosis

Route Of Administrations Covered:

  • Oral
  • Sub-cutaneous
  • Intravenous
  • Intramuscular
  • Other Route Of Administrations

End Users Covered:

  • Research Organizations
  • Hospitals & Clinics
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Turner Syndrome Market, By Type

  • 5.1 Introduction
  • 5.2 Mosaic Turner Syndrome
  • 5.3 Classical Turner Syndrome

6 Global Turner Syndrome Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Oxandrolone
  • 6.3 Oxandrin
  • 6.4 Norditropin
  • 6.5 Somatropin
  • 6.6 Genotropin
  • 6.7 Humatrope
  • 6.8 Zomacton
  • 6.9 Nutropin

7 Global Turner Syndrome Market, By Therapy Type

  • 7.1 Introduction
  • 7.2 Progesterone Replacement Therapy
  • 7.3 Oestrogen Replacement Therapy
  • 7.4 Growth Hormone Therapy
  • 7.5 Psychological Therapy
  • 7.6 Other Therapy Types

8 Global Turner Syndrome Market, By Diagnosis

  • 8.1 Introduction
  • 8.2 Physical Examination
  • 8.3 Karyotyping
  • 8.4 Prenatal Testing
    • 8.4.1 Amniocentesis
    • 8.4.2 Ultrasound Test
    • 8.4.3 Chorionic Villus Sampling
  • 8.5 Other Diagnosis

9 Global Turner Syndrome Market, By Route Of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Sub-cutaneous
  • 9.4 Intravenous
  • 9.5 Intramuscular
  • 9.6 Other Route Of Administrations

10 Global Turner Syndrome Market, By End User

  • 10.1 Introduction
  • 10.2 Research Organizations
  • 10.3 Hospitals & Clinics
  • 10.4 Academic Institutes
  • 10.5 Other End Users

11 Global Turner Syndrome Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Smiths Group
  • 13.2 Pfizer Inc.
  • 13.3 Rocket Medical PLC
  • 13.4 Medtronic
  • 13.5 Novo Nordisk
  • 13.6 Sanofi
  • 13.7 Cooper Pharma
  • 13.8 Eli Lilly and Company
  • 13.9 Genentech
  • 13.10 Lupin Pharmaceuticals Inc
  • 13.11 Sandoz International GmbH
  • 13.12 AbbVie Inc.
  • 13.13 Codexis
  • 13.14 Merck & Co.
  • 13.15 American Gene Technologies
  • 13.16 Johnson & Johnson Services Inc
  • 13.17 F. Hoffmann-La Roche Limited
  • 13.18 Ultragenyx Pharmaceutical
  • 13.19 Abbott Laboratories
  • 13.20 BioMarin

List of Tables

  • Table 1 Global Turner Syndrome Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Turner Syndrome Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Turner Syndrome Market Outlook, By Mosaic Turner Syndrome (2021-2030) ($MN)
  • Table 4 Global Turner Syndrome Market Outlook, By Classical Turner Syndrome (2021-2030) ($MN)
  • Table 5 Global Turner Syndrome Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 6 Global Turner Syndrome Market Outlook, By Oxandrolone (2021-2030) ($MN)
  • Table 7 Global Turner Syndrome Market Outlook, By Oxandrin (2021-2030) ($MN)
  • Table 8 Global Turner Syndrome Market Outlook, By Norditropin (2021-2030) ($MN)
  • Table 9 Global Turner Syndrome Market Outlook, By Somatropin (2021-2030) ($MN)
  • Table 10 Global Turner Syndrome Market Outlook, By Genotropin (2021-2030) ($MN)
  • Table 11 Global Turner Syndrome Market Outlook, By Humatrope (2021-2030) ($MN)
  • Table 12 Global Turner Syndrome Market Outlook, By Zomacton (2021-2030) ($MN)
  • Table 13 Global Turner Syndrome Market Outlook, By Nutropin (2021-2030) ($MN)
  • Table 14 Global Turner Syndrome Market Outlook, By Therapy Type (2021-2030) ($MN)
  • Table 15 Global Turner Syndrome Market Outlook, By Progesterone Replacement Therapy (2021-2030) ($MN)
  • Table 16 Global Turner Syndrome Market Outlook, By Oestrogen Replacement Therapy (2021-2030) ($MN)
  • Table 17 Global Turner Syndrome Market Outlook, By Growth Hormone Therapy (2021-2030) ($MN)
  • Table 18 Global Turner Syndrome Market Outlook, By Psychological Therapy (2021-2030) ($MN)
  • Table 19 Global Turner Syndrome Market Outlook, By Other Therapy Types (2021-2030) ($MN)
  • Table 20 Global Turner Syndrome Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 21 Global Turner Syndrome Market Outlook, By Physical Examination (2021-2030) ($MN)
  • Table 22 Global Turner Syndrome Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 23 Global Turner Syndrome Market Outlook, By Prenatal Testing (2021-2030) ($MN)
  • Table 24 Global Turner Syndrome Market Outlook, By Amniocentesis (2021-2030) ($MN)
  • Table 25 Global Turner Syndrome Market Outlook, By Ultrasound Test (2021-2030) ($MN)
  • Table 26 Global Turner Syndrome Market Outlook, By Chorionic Villus Sampling (2021-2030) ($MN)
  • Table 27 Global Turner Syndrome Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 28 Global Turner Syndrome Market Outlook, By Route Of Administration (2021-2030) ($MN)
  • Table 29 Global Turner Syndrome Market Outlook, By Oral (2021-2030) ($MN)
  • Table 30 Global Turner Syndrome Market Outlook, By Sub-cutaneous (2021-2030) ($MN)
  • Table 31 Global Turner Syndrome Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 32 Global Turner Syndrome Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 33 Global Turner Syndrome Market Outlook, By Other Route Of Administrations (2021-2030) ($MN)
  • Table 34 Global Turner Syndrome Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Turner Syndrome Market Outlook, By Research Organizations (2021-2030) ($MN)
  • Table 36 Global Turner Syndrome Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 37 Global Turner Syndrome Market Outlook, By Academic Institutes (2021-2030) ($MN)
  • Table 38 Global Turner Syndrome Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.